Loading...
Market
GSK New COVID-19 Vaccine Sales in 2025
2
Resolution / Starting Odds
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
GSK annual financial reports
Story
GSK Secures Full Rights to Develop COVID-19 and Influenza Vaccines from CureVac
Jul 3, 2024, 06:30 AM
GlaxoSmithKline (GSK) has announced a new licensing agreement with CureVac, securing full rights to develop and manufacture COVID-19 and influenza vaccines. This strategic investment in vaccine platform technologies aims to enhance GSK's ability to match the best platform to each pathogen, ultimately helping to prevent illness in more people worldwide.
View original story
Similar markets
COVID-19 vaccine • 33%
Flu vaccine • 33%
Other mRNA vaccines • 33%
Less than $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
More than $300 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%